To obtain Food and Drug Administration approval for the treatment of cognitive impairments associated with schizophrenia, a drug will need to demonstrate benefits beyond those that may be documented on objective cognitive tests. Interview-based measures of cognition such as the Cognitive Assessment Interview (CAI) are candidate coprimary outcome measures.

Ventura J, Reise SP, Keefe RSE, Hurford IM, Wood RC, Bilder RM. The Cognitive Assessment Interview (CAI):  Reliability and validity of a brief interview-based measure of cognition.  Schizophrenia Bulletin, 2013; 39(3): 583-591. (PMCID: PMC3627764).